Takeaway

• In the IMCgp100-202 phase III trial, the bispecific fusion protein tebentafusp showed a clinically meaningful improvement in OS as first-line treatment of metastatic uveal melanoma (UM).

Why this matters

• There is no standard therapy for UM, representing 3-5% of melanoma cases.
• About half of the patients with metastatic UM...